These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7646931)

  • 1. Modulation of the antitumour activity of cisplatin alone and in combination with 5-fluoro-2'-deoxyuridine by N-phosphonacetyl-L-aspartate in murine colon carcinoma no. 26.
    Van Laar JA; Mayhew EG; Cao S; Durrani FA; Peters GJ; Rustum YM
    Eur J Cancer; 1995 Jun; 31A(6):974-6. PubMed ID: 7646931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26.
    van Laar JA; Durrani FA; Rustum YM
    Cancer Res; 1993 Apr; 53(7):1560-4. PubMed ID: 8453623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of the antitumor-activity of 5-Fluorouracil and cisplatinum by N-phosphonacetyl-L-aspartate in the murine colon-carcinoma number-26.
    Durrani F; Cao S; Vanlaar J; Rustum Y
    Int J Oncol; 1994 Nov; 5(5):1065-8. PubMed ID: 21559681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of fluoropyrimidine Schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma.
    Cao S; Frank C; Rustum YM
    J Natl Cancer Inst; 1996 Apr; 88(7):430-6. PubMed ID: 8618234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model.
    van Laar JA; van der Wilt CL; Rustum YM; Noordhuis P; Smid K; Pinedo HM; Peters GJ
    Clin Cancer Res; 1996 Aug; 2(8):1327-33. PubMed ID: 9816304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
    Erlichman C; Vidgen D
    Biochem Pharmacol; 1984 Oct; 33(20):3177-81. PubMed ID: 6487365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon-alpha-2a against human colon cancer cell lines.
    Wadler S; Mao X; Bajaj R; Hallam S; Schwartz EL
    Mol Pharmacol; 1993 Nov; 44(5):1070-6. PubMed ID: 8246910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
    Van Echo DA; Diggs CH; Scoltock M; Wiernik PH
    Cancer Treat Rep; 1980; 64(2-3):339-42. PubMed ID: 7407767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance.
    Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Casper ES; Young CW
    Cancer Res; 1983 May; 43(5):2317-21. PubMed ID: 6187448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer.
    Mann GB; Hortobagyi GN; Buzdar AU; Yap HY; Valdivieso M
    Cancer; 1985 Sep; 56(6):1320-4. PubMed ID: 4027872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro cytotoxic effect of N-(phosphonacetyl)-L-aspartic acid in liposome against C-26 murine colon carcinoma.
    Kim JS; Heath TD
    Arch Pharm Res; 2000 Apr; 23(2):167-71. PubMed ID: 10836745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
    Chan TC; Markman M; Cleary S; Howell SB
    Cancer Res; 1986 Jun; 46(6):3168-72. PubMed ID: 3698032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A possible role for topoisomerase II in cell death and N-phosphonoacetyl-L-aspartate-resistance frequency and its enhancement by 1-beta-D-arabinofuranosyl cytosine and 5-fluoro-2'-deoxyuridine.
    Goz B; Bastow KF
    Mutat Res; 1997 Aug; 384(2):89-106. PubMed ID: 9298118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
    Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.
    Cao S; Rustum YM; Spector T
    Cancer Res; 1994 Mar; 54(6):1507-10. PubMed ID: 8137256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of low-dose PALA in biochemical modulation.
    O'Dwyer PJ
    Pharmacol Ther; 1990; 48(3):371-80. PubMed ID: 2084707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma.
    Carroll DS; Gralla RJ; Kemeny NE
    Cancer Treat Rep; 1980; 64(2-3):349-51. PubMed ID: 7407769
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
    Fleming RA; Capizzi RL; Muss HB; Smith S; Fernandes DJ; Homesley H; Loggie BW; Case L; Morris R; Russell GB; Richards F
    Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of the combination, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer.
    Rubin J; Schutt AJ; O'Connell MJ; Gertz MA; Moertel CG
    Am J Clin Oncol; 1984 Oct; 7(5):523-5. PubMed ID: 6507373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
    Chiuten DF; Miller A; Valdivieso M; Loo TL; Bedikian A; Bodey GP; Benvenuto JA; Freireich EJ
    Am J Clin Oncol; 1985 Aug; 8(4):332-5. PubMed ID: 4083263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.